Your session is about to expire
← Back to Search
Neuromodulation
Neuromodulation for Depression
N/A
Waitlist Available
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Normal or corrected-to normal vision and hearing
For group with depression, current diagnosis of depression
Must not have
Active significant medical illness or neurological disorder
For healthy control group, any current or past history of mood disorders
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 hours
Summary
This trial is testing if a new treatment, LIFUP, can change negative cognition in depression by modulating the activity of the brain's Default Mode Network. The study will investigate if this treatment can decrease mind-wandering and increase mindfulness.
Who is the study for?
This trial is for right-handed adults aged 18-64 with a current diagnosis of depression. Participants must have normal or corrected-to-normal vision and hearing, without significant medical illnesses, neurological disorders, or MRI scan contraindications like metal implants.
What is being tested?
The study tests the BrainSonix Pulsar 1002's ability to modulate brain activity in the posterior cingulate cortex (PCC) to potentially reduce negative mind-wandering associated with depression. It will explore if altering PCC activity can affect mindfulness and cognitive-affective tasks.
What are the potential side effects?
Potential side effects are not explicitly listed but may include discomfort from wearing the device, headache, dizziness, or other sensations related to non-invasive brain stimulation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My vision and hearing are normal, or corrected to be normal.
Select...
I am currently diagnosed with depression.
Select...
I am between 18 and 64 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a serious illness or brain disorder.
Select...
I have never had a mood disorder.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Default mode network activation during task
Negative self-judgment frequency during task
Rumination
Secondary study objectives
Default mode network connectivity
Depressive Symptoms
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: Active LIFUPActive Control1 Intervention
All participants will receive active modulation of the posterior cingulate cortex (PCC) during Visit 3 or 4 (order counterbalanced).
Group II: Sham LIFUPPlacebo Group1 Intervention
All participants will receive sham modulation of the posterior cingulate cortex (PCC) during Visit 3 or 4 (order counterbalanced).
Find a Location
Who is running the clinical trial?
Massachusetts General HospitalLead Sponsor
3,000 Previous Clinical Trials
13,308,468 Total Patients Enrolled
190 Trials studying Depression
33,812 Patients Enrolled for Depression
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a serious illness or brain disorder.My vision and hearing are normal, or corrected to be normal.I am either male or female.You cannot have an MRI scan if you have metal implants, are claustrophobic or weigh more than 250 pounds.I am currently diagnosed with depression.You must be right-handed.I have never had a mood disorder.I am between 18 and 64 years old.
Research Study Groups:
This trial has the following groups:- Group 1: Active LIFUP
- Group 2: Sham LIFUP
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger